Back to search results

A Study of AZD0780 and AZD4954 in Healthy Adults

This study is looking for healthy adults, aged 18 to 55, to understand how two drugs, AZD0780 (also known as Laroprovstat) and AZD4954, affect each other in the body. Specifically, researchers want to see how taking one drug changes the levels of the other drug in your system. This is measured by looking at how much of the drug is in your blood over time (called pharmacokinetics or PK). The study will measure the total amount of AZD4954 and Laroprovstat in your body (AUCinf) and the highest level they reach (Cmax). There are 32 participants planned for this study, but the current recruitment status is unclear.

Study design
This is an open-label study, meaning you and the researchers will know which treatments you are receiving. It involves two groups of participants, each receiving treatments in a specific order.
What's involved
You will go through a screening period, two treatment periods where you receive the study drugs, and follow-up visits. The primary measurements for AZD4954 are taken from Day 1 to Day 41, and for Laroprovstat from Day 1 to Day 25.
Compensation
Not stated in the trial record.
Follow-up
The primary measurements for AZD4954 are taken until Day 41, and for Laroprovstat until Day 25.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07513571

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults

Completed
PHASE1Ages 18–55InterventionalTreatment
AstraZeneca
~31 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:AZD4954Laroprovstat

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Area under concentration time curve from time 0 to infinity (AUCinf) of AZD4954
Measured over Cohort 1: Day 1 to Day 41
+3 more outcomes measured

Conditions

Healthy Participants

Explore related trials

Healthy Participants

Where it's being run

1 sites across 1 states
California1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All females must have a negative pregnancy test at the Screening Visit.
Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception.
Females of non-childbearing potential must be confirmed as postmenopausal or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation or tubal occlusion.
Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods.
Have a body mass index between 18 and 35 kg/m2 inclusive and weigh at least 50 kg.

Exclusion

History of any clinically important disease or disorder.
History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
Participants with known bleeding or coagulation disorders.
Any clinically important abnormalities in laboratory values, clinical chemistry, hematology, urinalysis results, or vital signs.
Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram at screening.
Participants who are current smokers or have used any tobacco or nicotine-containing products (including e-cigarettes) within 3 months prior to screening; known or suspected history of alcohol or drug abuse; positive screen for drugs of abuse, alcohol, or cotinine at screening or on each admission to the Clinical Unit.
History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity or history of hypersensitivity to drugs of a similar chemical structure or class to AZD4954 or laroprovstat.
Participants who have previously received AZD4954.
Treatment with any lipid-lowering therapy or laroprovstat within the 3 months prior to the Screening Visit.

What this trial measures

  • Area under concentration time curve from time 0 to infinity (AUCinf) of AZD4954Cohort 1: Day 1 to Day 41

    To assess the effect of a single dose of oral laroprovstat on the PK of a single dose of oral AZD4954 in healthy participants.

  • Maximum observed drug concentration (Cmax) of AZD4954Cohort 1: Day 1 to Day 41

    To assess the effect of a single dose of oral laroprovstat on the PK of a single dose of oral AZD4954 in healthy participants.

  • AUCinf of laroprovstatCohort 2: Day 1 to Day 25

    To assess the effect of a single dose of oral AZD4954 on the PK of a single dose of oral laroprovstat in healthy participants.

  • Cmax of laroprovstatCohort 2: Day 1 to Day 25

    To assess the effect of a single dose of oral AZD4954 on the PK of a single dose of oral laroprovstat in healthy participants.